In this regard, various authors reported an independent prognostic effect for CD3, CD4 or CD8 T cells in HPV-positive OPSCC patients (22, 23) demonstrating a significant role of anti-tumor immune responses not only for anti-PD1 therapies but for OPSCC tumor control and response to RCTx in general. The gene discussed is CD8A; the disease is neoplasm.